Hematopoietic stem cell transplants (HSCT) are becoming more widespread as a result of
optimization of conditioning regimens and prevention of short-term complications with …

The indications for hematopoietic stem cell transplantation (HSCT) continue to expand.
However, the risk for pulmonary complications post-HSCT continues to be high. Early …

Introduction: Progress in allogeneic hematopoietic stem cell transplantation (HSCT)
procedures has been associated with improved survival in HSCT recipients. However, they …

Hematopoietic stem cell transplantation (HSCT) is a widely available treatment for a variety
of malignant and nonmalignant disorders. The treatment outcome is affected by the type of …

More than a million hematopoietic cell transplants (HCTs) have been performed worldwide
to treat a spectrum of benign and malignant diseases. 1, 2 Survival rates after HCT are …

Background Most reports addressing pulmonary complications (PCs) in hematopoietic stem
cell transplant (HSCT) recipients have focused on allogeneics. This study describes the …

Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of
malignant and nonmalignant conditions. pulmonary complications, infectious and …

Pulmonary complications after hematopoietic stem cell transplantation (HSCT) are important
sources of morbidity and mortality. Improvements in infection-related complications have …

Background: Survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are
at risk for pulmonary adverse events. Data on late-onset noninfectious pulmonary …

Hematopoietic (blood and marrow) stem cell transplantation (HSCT) is an important,
potentially curative treatment option for patients with benign and malignant hematologic …